Follow up idea, see related idea
After 5 wave impulse down and two month accumulation phase below IPO level sideways,
expect trend reversal into bull market, the downtrend channel got broken and tested on weekly timeframe.
The first human got crispered in china. USA will follow in 2017, I speculate on public awareness and solid growth, maybe hype.
In case of bull market, we got the possible pitchfork
After 5 wave impulse down and two month accumulation phase below IPO level sideways,
expect trend reversal into bull market, the downtrend channel got broken and tested on weekly timeframe.
The first human got crispered in china. USA will follow in 2017, I speculate on public awareness and solid growth, maybe hype.
In case of bull market, we got the possible pitchfork
Note
and back above IPO!!! i love it <3Note
wyckoff playing out nicely, can buy on dips for reaccumulation 16-17$ rangetrailing stop below pitchfork, this stock keeps giving for weeks now with great volatility
Note
more media attention wired.co.uk/article/crispr-cas9-technique-explained
Note
crispr again in the news afterNote
crispr again on all news sites after National Academy of Sciences releases Report "Human Genome Editing: Science, Ethics, and Governance"Note
CRISPR patent goes to Broad Institute of Cambridge -> EDIT technologyreview.com/s/603662/patent-office-hands-win-in-crispr-battle-to-broad-institute/Note
Editas Medicine announces that its offering of 4M shares priced at $22.50 per share.seekingalpha.com/news/3251923-editas-medicine-prices-90m-offering
resistance 0.5 fib keylevel at 28.20
Support 20.00-22.50
Note
doubled my position hereRelated publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.